论文部分内容阅读
肾细胞癌(RCC)的发生和进展机制目前仍不完全清楚。肾癌细胞对放疗、化疗和生物治疗均不敏感,并且有高转移率及转移后的低生存率的特点。目前肾癌术后预后评估的方法主要依靠临床和病理学表现,尚无敏感的标记物来预测肿瘤的复发或转移。Ⅱ型跨膜糖蛋白CD70是肿瘤坏死因子家族成员,主要表达于抗原提呈细胞(APCs),如B细胞,DC细胞;少量的T淋巴细胞和多种肿瘤细胞。CD70在肾癌细胞内的特异高表达及在正常肾组织内不表达,这为肾癌的诊断,治疗和预后判断提供了理想的途径。本文对CD70的研究现状和其临床应用前景综述如下。
The pathogenesis and progression of renal cell carcinoma (RCC) are still not fully understood. Renal cancer cells are not sensitive to radiotherapy, chemotherapy and biological therapy, and have the characteristics of high metastasis rate and low survival rate after metastasis. At present, the method of postoperative prognosis of renal cell carcinoma relies mainly on clinical and pathological findings, and there is no sensitive marker to predict tumor recurrence or metastasis. Type II transmembrane glycoprotein CD70 is a member of tumor necrosis factor family, mainly expressed in antigen presenting cells (APCs), such as B cells, DC cells; a small amount of T lymphocytes and a variety of tumor cells. The high expression of CD70 in renal cell carcinoma and its expression in normal renal tissue, which provides an ideal way for the diagnosis, treatment and prognosis of renal cell carcinoma. This article on CD70 research status and its clinical application prospects are summarized below.